Axcentua
Desconocido
EPC-TM-NET: Targeting the tumour microenvironment to improve pancreatic cancer prognosis
Axcentua Pharmaceuticals AB
participó en un
FP7:
Pancreatic cancer is one of the most lethal human cancers with a five-year survival rate of less than 5%. Late presentation and a high level...
Financiado
Financiado
* No se disponen de datos de la empresa actual.